Journal of International Psychiatry

Objective: To investigate the effect of ziprasidone combined with lithium carbonate in the treatment of patients with bipolar disorder type I and acute manic episode, and analyze the impact on serum homocysteine (Hcy) and brain-derived neurotrophic factor (BDNF) levels and cognitive function. Methods: 102 patients with bipolar disorder type I acute manic episodes from January 2021 to December 2023 were selected. They were randomly divided into the combination group (50 patients treated with ziprasidone combined with lithium carbonate) and the control group (50 patients treated with lithium carbonate). Both groups were treated for 8 weeks. The two groups were compared on therapeutic effects, serum Hcy and BDNF levels, Bech-Rafaelsen mania rating scale (BRMS) scores, young mania rating scale (YMRS) scores, repeatable battery for the assessment of neuropsychological status (RBANS) scores and adverse reactions. Results: Compared with the control group, the efficiency of the combination group was higher (92.31% vs 74.00%, P<0.05). Compared with the control group, the Hcy level was lower and BDNF level was higher of the combination group (P<0.05). Compared with the control group, the combination group had lower BRMS score and YMRS score, and higher RBANS score (P<0.05). The total incidence rates of adverse reactions in the combination group and the control group were 13.46% and 10.00%, without significant difference between the groups (P>0.05). Conclusion: Ziprasidone combined with lithium carbonate can significantly improve the therapeutic effect on bipolar disorder type I with acute manic episode, as well as central nervous system and cognitive function.

Bipolar disorder type I; Manic episode; Ziprasidone; Lithium carbonate; Homocysteine; Brain-derived neurotrophic factor